Financials data is unavailable for this security.
View more
Year on year Dermapharm Holding SE had net income fall -53.54% from 134.24m to 62.37m despite a 10.79% increase in revenues from 1.02bn to 1.14bn. An increase in the selling, general and administrative costs as a percentage of sales from 28.39% to 36.87% was a component in the falling net income despite rising revenues.
| Gross margin | 64.32% |
|---|---|
| Net profit margin | 7.14% |
| Operating margin | 16.89% |
| Return on assets | 3.74% |
|---|---|
| Return on equity | 15.48% |
| Return on investment | 4.52% |
More ▼
Cash flow in EURView more
In 2023, Dermapharm Holding SE increased its cash reserves by 5.10%, or 7.71m. The company earned 218.60m from its operations for a Cash Flow Margin of 19.25%. In addition the company generated 204.54m cash from financing while 415.43m was spent on investing.
| Cash flow per share | 3.33 |
|---|---|
| Price/Cash flow per share | 9.45 |
| Book value per share | 10.24 |
|---|---|
| Tangible book value per share | -10.31 |
More ▼
Balance sheet in EURView more
| Current ratio | 1.58 |
|---|---|
| Quick ratio | 0.7835 |
| Total debt/total equity | 1.96 |
|---|---|
| Total debt/total capital | 0.6596 |
More ▼
Growth rates in EUR
SmartText is unavailable
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 57.06% |
| EPS growth(5 years) | -3.86 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -32.59 |
More ▼
